Basilea Pharmaceutica AG: Basilea reports strong 2020 financial results and significant progress in the clinical pipeline of its oncology assets
Operating loss reduced by over 50% to CHF 8.2 million
Improved operating cash flow by 15%, CHF 167 million year-end cash and financial investments
Established clinical proof of concept for derazantinib as monotherapy in first cancer indication
2021 guidance: expecting 38% - 51% growth in Cresemba and Zevtera non-deferred revenue contributions, stable expenses and 2021 year-end cash position of
CHF 110 - 120 million
Basel, Switzerland, February 16, 2021
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today its financial results for the financial year ended December 31, 2020.
David Veitch, Chief Executive Officer, said: Despite the coronavirus pandemic, we have remained fully operational and have achieved significant milestones throughout 2020, both in the commercialization of our two marketed brands, Cresemba and Zevtera, as well
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Basilea reports strong 2020 financial results and significant progress in the clinical pipeline .
Basilea Pharmaceutica AGFebruary 16, 2021 GMT
Double-digit growth in Cresemba and Zevtera non-deferred revenue contributions
Operating loss reduced by over 50% to CHF 8.2 million
Improved operating cash flow by 15%, CHF 167 million year-end cash and financial investments
Established clinical proof of concept for derazantinib as monotherapy in first cancer indication
2021 guidance: expecting 38% - 51% growth in Cresemba and Zevtera non-deferred revenue contributions, stable expenses and 2021 year-end cash position of CHF 110 - 120 million
Basel, Switzerland, February 16, 2021
ADVERTISEMENT
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today its financial results for the financial year ended December 31, 2020.